Literature DB >> 31608951

The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: New features and the ‘Ten Commandments’ of the 2019 Guidelines are discussed by Professor Peter J. Grant and Professor Francesco Cosentino, the Task Force chairmen.

Peter J Grant1, Francesco Cosentino2.   

Abstract

Entities:  

Year:  2019        PMID： 31608951     DOI： 10.1093/eurheartj/ehz687

Source DB:  PubMed          Journal:  Eur Heart J        ISSN： 0195-668X            Impact factor:   29.983


× No keyword cloud information.
  31 in total

1.  Effectiveness of sodium-glucose co-transporter-2 inhibitors on ischaemic heart disease.

Authors:  Yun Shen; Jian Zhou; Lizheng Shi; Elizabeth Nauman; Peter T Katzmarzyk; Eboni G Price-Haywood; Ronald Horswell; San Chu; Shengping Yang; Alessandra N Bazzano; Somesh Nigam; Gang Hu
Journal:  Diabetes Obes Metab       Date:  2020-03-31       Impact factor: 6.577

2.  Deficiency of natural anticoagulants: how should we manage cardiovascular prevention?

Authors:  Francesco Paciullo; Andrea Baccolo
Journal:  Intern Emerg Med       Date:  2021-03-23       Impact factor: 3.397

3.  Short and long-term prognosis of admission hyperglycemia in patients with and without diabetes after acute myocardial infarction: a retrospective cohort study.

Authors:  Hanzohra Upur; Jia-Li Li; Xiao-Guang Zou; Yu-Ying Hu; He-Yin Yang; Alimujiang Abudoureyimu; Anwar Abliz; Mamatili Abdukerim; Min Huang
Journal:  Cardiovasc Diabetol       Date:  2022-06-23       Impact factor: 8.949

4.  Application of 2021 American Diabetes Association Glycemic Treatment Clinical Practice Recommendations in Primary Care.

Authors:  Caitlin Colling; Steven J Atlas; Deborah J Wexler
Journal:  Diabetes Care       Date:  2021-05-20       Impact factor: 17.152

5.  Prognosis of unrecognised myocardial infarction determined by electrocardiography or cardiac magnetic resonance imaging: systematic review and meta-analysis.

Authors:  Yu Yang; Wensheng Li; Hailan Zhu; Xiong-Fei Pan; Yunzhao Hu; Clare Arnott; Weiyi Mai; Xiaoyan Cai; Yuli Huang
Journal:  BMJ       Date:  2020-05-07

6.  Optimising Secondary Prevention and Cardiac Rehabilitation for Atherosclerotic Cardiovascular Disease During the COVID-19 Pandemic: A Position Statement From the Cardiac Society of Australia and New Zealand (CSANZ).

Authors:  Stephen J Nicholls; Mark Nelson; Carolyn Astley; Tom Briffa; Alex Brown; Robyn Clark; David Colquhoun; Robyn Gallagher; David L Hare; Sally Inglis; Michael Jelinek; Adrienne O'Neil; Rosy Tirimacco; Margarite Vale; Julie Redfern
Journal:  Heart Lung Circ       Date:  2020-04-30       Impact factor: 2.975

7.  Associations of aspirin, statins and metformin with lung cancer risk and related mortality.

Authors:  Armin Frille; Adrien Costantini; Katherina B Sreter
Journal:  Breathe (Sheff)       Date:  2021-06

8.  Impacts of Pre-Diabetes or Prehypertension on Subsequent Occurrence of Cardiovascular and All-Cause Mortality among Population without Cardiovascular Diseases.

Authors:  Yu-Qing Huang; Lin Liu; Cheng Huang; Yu-Ling Yu; Kenneth Lo; Jia-Yi Huang; Chao-Lei Chen; Ying-Ling Zhou; Ying-Qing Feng
Journal:  Diabetes Metab Syndr Obes       Date:  2020-05-21       Impact factor: 3.168

9.  Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial.

Authors:  Atsushi Tanaka; Michio Shimabukuro; Yosuke Okada; Kazuhiro Sugimoto; Akira Kurozumi; Keiichi Torimoto; Hiroyuki Hirai; Koichi Node
Journal:  Cardiovasc Diabetol       Date:  2020-06-13       Impact factor: 9.951

10.  INtegration of care for reaching targetS In Diabetic patiEnts: Design of the INSIDE Study.

Authors:  Marco Comaschi; Andrea Di Lenarda; Gerardo Medea; Alberto Aglialoro; Domenico Cucinotta; Michele Gulizia; Giacomo Vespasiani; Guerrino Zuin; Antonio Nicolucci; Federico Spandonaro; Aldo Pietro Maggioni
Journal:  Diabetes Ther       Date:  2019-11-22       Impact factor: 2.945
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.